<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04589078</url>
  </required_header>
  <id_info>
    <org_study_id>CB-17-08/05</org_study_id>
    <nct_id>NCT04589078</nct_id>
  </id_info>
  <brief_title>Polyp REcognition Assisted by a Device Interactive Characterization Tool - The PREDICT Study</brief_title>
  <acronym>PREDICT</acronym>
  <official_title>Polyp REcognition Assisted by a Device Interactive Characterization Tool - The PREDICT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cosmo Artificial Intelligence-AI Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cosmo Pharmaceuticals NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diminutive colorectal polyps (≤ 5 mm) represent most of the polyps detected during&#xD;
      colonoscopy, especially in the rectum-sigmoid tract. The characterization of these polyps by&#xD;
      virtual chromoendoscopy is recognized as a key element for innovative imaging techniques. As&#xD;
      a matter of facts diminutive colorectal polyps are very frequent and, if located in the&#xD;
      rectosigmoid colon, they present a very low malignant risk (0.3% of evolution towards&#xD;
      advanced adenoma and up to 0.08% of evolution towards invasive carcinoma). The real-time&#xD;
      characterization would allow to identify the lowest risk polyps (hyperplastic subtype), to&#xD;
      leave them in situ or, if resected, not to send them for histological examination, allowing a&#xD;
      huge saving in healthcare associated costs.&#xD;
&#xD;
      Recently, the American Society for Gastrointestinal Endoscopy (ASGE) Technology Committee&#xD;
      established the Preservation and Incorporation of Valuable endoscopic Innovations (PIVI)&#xD;
      document, specific for real-time histological assessment for tiny colorectal polyps, to&#xD;
      establish reference quality thresholds. Two performance standards have been developed to&#xD;
      guide the use of advanced imaging:&#xD;
&#xD;
        1. for diminutive polyps to be resected and discarded without pathologic assessment,&#xD;
           endoscopic technology (when used with high confidence) used to determine histology of&#xD;
           polyps ≤ 5mm in size, when combined with the histopathology assessment of polyps &gt; 5 mm&#xD;
           in size, should provide a ≥ 90% agreement in assignment of post-polypectomy surveillance&#xD;
           intervals when compared to decisions based on pathology assessment of all identified&#xD;
           polyps;&#xD;
&#xD;
        2. in order for a technology to be used to guide the decision to leave suspected&#xD;
           rectosigmoid hyperplastic polyps ≤ 5 mm in size in place (without resection), the&#xD;
           technology should provide ≥ 90% negative predictive value (when used with high&#xD;
           confidence) for adenomatous histology.&#xD;
&#xD;
      Computer-Aided-Diagnosis (CAD) is an artificial intelligence-based tool that would allow&#xD;
      rapid and objective characterization of these lesions. The GI Genius CADx was developed to&#xD;
      help endoscopists in their clinical practices for polyps characterization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 8, 2020</start_date>
  <completion_date type="Actual">December 22, 2020</completion_date>
  <primary_completion_date type="Actual">December 22, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Negative Predictive Value of histology prediction on diminutive (≤5 mm) rectosigmoid polyps</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Agreement in assignment of post-polypectomy surveillance intervals</measure>
    <time_frame>1 day</time_frame>
    <description>Agreement in assignment of post-polypectomy surveillance intervals according to established guidelines between:&#xD;
the assignment identified according to the combined&#xD;
GI Genius CADx histology prediction for diminutive (≤5 mm) polyps and&#xD;
histology for larger polyps (&gt; 5 mm), and&#xD;
the assignment identified according to histology only.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sensitivity, Specificity, Accuracy, PPV and NPV of GI Genius CADx histology prediction and endoscopist assessment on all the identified lesions</measure>
    <time_frame>1 day</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Artificial Intelligence</condition>
  <arm_group>
    <arm_group_label>Interficial Intelligence</arm_group_label>
    <description>Each patient will undergo standard white-light colonoscopy with the support of the latest version of the CE marked GI Genius CADe available.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GI Genius CADe system</intervention_name>
    <description>Each patient will undergo standard white-light colonoscopy with the support of the latest version of the CE marked GI Genius CADe available.</description>
    <arm_group_label>Interficial Intelligence</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 40-80 undergoing colonoscopy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 40-80 undergoing screening colonoscopy for CRC&#xD;
&#xD;
          -  Ability to provide written, informed consent (approved by EC) and understand the&#xD;
             responsibilities of trial participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subjects positive to Fecal Immunochemical Test or Fecal Occult Blood Test;&#xD;
&#xD;
          -  subjects undergoing CRC surveillance colonoscopy&#xD;
&#xD;
          -  subject at high risk for CRC&#xD;
&#xD;
          -  subjects with a personal history of CRC, IBD or hereditary polyposic or non-polyposic&#xD;
             syndromes;&#xD;
&#xD;
          -  patients with previous resection of the sigmoid rectum;&#xD;
&#xD;
          -  patients on anticoagulant therapy, which precludes resection / removal operations due&#xD;
             to histopathological findings;&#xD;
&#xD;
          -  patients who perform an emergency colonoscopy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Endoscopy Unit, Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

